Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
Hybrid — also manufactures internal programs
Compare mRNA/LNP CDMOs in Europe
Compare mRNA/LNP CDMOs in Germany
Compare Biologics CDMOs in Europe
Compare Biologics CDMOs in Germany
Compare Cell Therapy CDMOs in Europe
Compare Cell Therapy CDMOs in Germany
22 confirmed programs
· 11 sponsors
· Last scored 2026-10-29
81.9
Signal Score
✓ FDA Inspections (2)
✓ Clinical Trials (22)
○ SEC Filings
○ Press
✓ EMA GMP (2)
○ MHRA GMP
✓ HC GMP (15)
Quick Facts: Merck KGaA / MilliporeSigma (CDMO)
- Signal Score
- 81.9/100 (as of 2026-10-29)
- Quality Compliance
- 98.9/100
- Headquarters
- Darmstadt, DE · St. Louis, MO
- Modalities
- mRNA, Biologics, Cell Therapy
- Active Programs
- 22 confirmed from ClinicalTrials.gov across 11 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Merck KGaA / MilliporeSigma (CDMO)
Life science tools company with CDMO services.
Signal Score & Pillar Breakdown
Quality Compliance
98.9
FDA Inspections2 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-04-28)
EMA GMP Certificates2 on record
Most Recent HC OutcomeCompliant · 2023-10-06
HC Attribution15 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Operations
72.3
22 active programs across 11 sponsors
Modalities: Cell Therapy, Biologics, mRNA
16 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
22 active programs across 11 sponsors · Modalities: Cell Therapy, Biologics, mRNA · 16 programs in advanced phases (Phase 2/3)
Programs
22
Sponsors11
ModalitiesmRNA, Biologics, Cell Therapy
22 active programs across 11 sponsors
Modalities: Cell Therapy, Biologics, mRNA
16 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT04792073
Study of Avelumab and/or Radiation Therapy in People With...
PHASE2
Active Not Recruiting
View all 22 programs →
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability
83.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Publicly traded — financial transparency
Capacity
63.0
3 manufacturing sites
Sites: Darmstadt, Germany, St. Louis, MO, Carlsbad, CA
Source: company profiles (manufacturing sites, modality breadth)
3 manufacturing sites
3 manufacturing sites
Merck KGaA / MilliporeSigma (CDMO) FDA Inspection History
2025-04
2025-03
NAI
VAI
OAI
| Date | Site | Type | 483 citations posted | Classification |
|---|---|---|---|---|
| 2025-04-28 |
Sigma-Aldrich Manufacturing LLC
Saint Louis, Missouri
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2025-03-14 |
Merck Life Science Technologies (Nantong) Co., Ltd.
Nantong
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
Source: FDA Data Dashboard · Retrieved Nov 21, 2026
Merck KGaA / MilliporeSigma (CDMO) EMA GMP Compliance 2 certificates
2024-05
2023-10
Compliant
Non-Compliant
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| DE_HH_01_GMP_2024_0040 | Merck KGaA | Germany | 2024-05-24 | COMPLIANT |
| DE_HE_01_GMP_2023_0055 | Merck KGaA | Germany | 2023-10-06 | COMPLIANT |
Source: EMA EudraGMDP · Retrieved Nov 21, 2026
Japan-accredited overseas site (PMDA)
biologics, general (non-sterile) · 2 sites · own products, not contract-manufacturing evidence
- Darmstadt, Germany · Merck KGaA — general (non-sterile) · valid to May 30, 2027
- Saint Louis, United States · Sigma-Aldrich Manufacturing, LLC — biologics · valid to Sep 25, 2027
PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. These approvals cover the company's own products; they are not evidence of contract manufacturing. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)
Clinical Activity 22 studies
NCT06110195
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head...
PHASE1
Terminated
NCT04792073
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel...
PHASE2
Active Not Recruiting
NCT04052204
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide...
PHASE1/PHASE2
Terminated
NCT03737721
The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With...
PHASE2
Terminated
NCT03747419
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
PHASE2
Terminated
NCT03409458
A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors...
PHASE1/PHASE2
Completed
NCT03271372
Adjuvant Avelumab in Merkel Cell Cancer
PHASE3
Active Not Recruiting
NCT02968940
Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate...
PHASE2
Completed
NCT02584829
Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With...
PHASE1/PHASE2
Terminated
NCT02083679
Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer
PHASE1
Terminated
NCT01390818
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally...
PHASE1
Completed
NCT01040832
EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve...
PHASE2
Completed
NCT00813943
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With...
PHASE2
Completed
NCT00689221
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With...
PHASE3
Completed
NCT00633529
Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment...
PHASE1
Completed
NCT00111839
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of...
PHASE2
Completed
NCT00132522
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate,...
PHASE1
Completed
NCT01077960
Safety and Efficacy Study of Serostim® Human Immunodeficiency...
PHASE3
Completed
NCT00071240
Growth Hormone to Increase Immune Function in People With HIV
PHASE2
Completed
NCT00294918
An Efficacy and Safety Trial of Serostim® in the Maintenance of the...
PHASE2/PHASE3
Completed
+ 2 more studies
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Hiring Activity 8 open roles Beta
From public job postings on the parent company's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
8
open roles
4
in manufacturing, quality, PD/MSAT, engineering or regulatory (50%)
Trend from Nov 29, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 28, 2027.
Since Nov 19, 2026: 0 new postings, 890 taken down.
By function
By site
Carlsbad, California, United States
profile site
1 mfg/ops · 1 PD/MSAT · 2 eng. · 3 other 7
1 mfg/ops · 1 PD/MSAT · 2 eng. · 3 other 7
Corsier-sur-Vevey, Vaud, Switzerland
· 1 other 1
· 1 other 1
Modality words in job titles
ADC1
Latest postings
Research Technician
Other (finance, HR, IT, other) · Carlsbad, California, United States
Operations Technician
Manufacturing & operations · Carlsbad, California, United States · posted Nov 18, 2026
Commercial Development Manager
Commercial, BD & client projects · Carlsbad, California, United States
Global Asset and Network Strategy Lead
Engineering & facilities · Carlsbad, California, United States · posted Nov 11, 2026
Research Technician
Other (finance, HR, IT, other) · Carlsbad, California, United States
Associate Engineer
Engineering & facilities · Carlsbad, California, United States
Internship ADC modeling
Other (finance, HR, IT, other) · Corsier-sur-Vevey, Vaud, Switzerland
GOglobal Program Electronics R&D 2026
Process development & MSAT · Carlsbad, California, United States
Coverage: read from the parent company's careers board and kept only postings at this business's sites (Carlsbad viral-vector site plus CDMO/ADC/bioconjugation titles; group Phenom site needs JSON-LD locations (backfilled up to 200 pages a day)). Roles outside those sites are left out, and some of this unit's roles may be missed.
Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source:
careers.emdgroup.com
· Checked Nov 20, 2026 · Tracking since Oct 26, 2026
Frequently Asked Questions About Merck KGaA / MilliporeSigma (CDMO)
How many FDA inspections does Merck KGaA / MilliporeSigma (CDMO) have on record?
CDMO Signal tracks 2 FDA inspections for Merck KGaA / MilliporeSigma (CDMO), sourced from the FDA inspection database. See the full inspection history above.
Has Merck KGaA / MilliporeSigma (CDMO) received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Merck KGaA / MilliporeSigma (CDMO).
Does Merck KGaA / MilliporeSigma (CDMO) hold EMA or MHRA GMP certificates?
CDMO Signal tracks 2 EMA GMP certificates for Merck KGaA / MilliporeSigma (CDMO).
How many clinical programs is Merck KGaA / MilliporeSigma (CDMO) linked to?
Merck KGaA / MilliporeSigma (CDMO) is associated with 22 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Merck KGaA / MilliporeSigma (CDMO)'s CDMO Signal Score?
Merck KGaA / MilliporeSigma (CDMO) has a Signal Score of 82/100, based on quality, operations, financial stability, and capacity data.
Evaluating Merck KGaA / MilliporeSigma (CDMO) for a manufacturing program?
Use the free AI matchmaker to compare Merck KGaA / MilliporeSigma (CDMO) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
ProBio
Pennington, NJ · Nanjing, CN
Signal Score: 64.0
mRNA, Biologics, CAR-T, Cell Therapy
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 90.1
Biologics, mRNA, Small Molecule API, Oral Solid Dose, High-Potency APIs, Sterile Fill-Finish
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 86.7
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 83.1
mRNA, Oligonucleotide, Biologics
Eurofins CDMO
Planegg, DE · San Diego, CA
Signal Score: 81.6
Biologics, Cell Therapy
Compare Merck KGaA / MilliporeSigma (CDMO) with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.